

20 **Corresponding Author:**

21 *Hsien-Yuan Chang, MD, MS

22 Division of Cardiology, Department of Internal Medicine, National Cheng Kung University

23 Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

24 No. 138, Shengli Rd., North Dist., Tainan City, Taiwan (R.O.C.)

25 TEL: +886-6-2353535 ext: 2389

26 FAX: +886-6-2753834

27 Email: doyeric0926@yahoo.com

28

29 *Chih-Chan Lin, MD

30 Division of Cardiology, Department of Internal Medicine, An Nan Hospital, China Medical

31 University, Tainan, Taiwan

32 No.66, Sec. 2, Changhe Rd., Annan Dist., Tainan City 709, Taiwan (R.O.C.)

33 TEL: +886-6-3553111 ext: 4644

34 FAX: +886-6-2753834

35 E-mail: cecillin0716@gmail.com

36

37 **Word count: 3,788**

38

39 **Clinical perspective**

40 A simple model based on computed tomography pulmonary angiography (CTPA) to
41 predict clinical deterioration in patients with acute pulmonary embolism (PE) is currently
42 lacking.

43 This retrospective study included 210 patients and used the model for calculating the
44 nearly totally obstructed segmental pulmonary arteries as an efficient and simple method
45 to predict clinical deterioration. This model added to the simplified PE severity index
46 (sPESI) has an increased predictive ability compared to the sPESI alone. CTPA images can
47 predict the clinical deterioration of patients with acute PE and may assist in clinical
48 decision-making.

49

50 **Abstract**

51 Hemodynamic instability may develop in patients with acute pulmonary embolism (PE)
52 days after the emboli event. Simplified methods to predict clinical deterioration are
53 currently lacking. This retrospective cohort study included patients diagnosed with acute.
54 The aim is to develop a simplified imaging model with good clinical accessibility to predict
55 the clinical deterioration of patients with acute PE. This study included patients with acute
56 PE under the International Classification of Disease, ninth or tenth revision. Seven models
57 based on computed tomography pulmonary angiography (CTPA) were developed based on
58 the location (central versus peripheral) and the degree (nearly total versus partial) of
59 obstruction. The outcome includes clinical deterioration, which is defined as death from PE,
60 cardiopulmonary resuscitation, mechanical ventilation, vasopressor therapy, thrombolysis,
61 catheter-directed therapy, and surgical embolectomy. Logistic regression analysis was used
62 to test the association between different models and clinical deterioration. The area under
63 the receiver operating characteristic curve (AUC) was used to test the predictive ability. The
64 category-free net reclassification improvement (NRI) and integrated discrimination
65 improvement (IDI) were used to quantify the improvement of the proposed models plus the
66 simplified Pulmonary Severity Index (sPESI) compared with the sPESI alone. Calculating the
67 nearly totally obstructed 20 peripheral arteries provides good predictive ability in the seven
68 models (AUC: 0.77). Calculating nearly totally obstructed 20 peripheral segments can predict

69 clinical deterioration. Obstruction on CTPA combined with the sPESI increased the ability to

70 predict clinical deterioration compared to the sPESI alone and may be used as guidance in

71 clinical decision-making.

72 Keywords: pulmonary embolism, computed tomography pulmonary angiography

73

74 **Manuscript text**

75 **Introduction**

76 Acute pulmonary embolism (PE), following myocardial infarction and stroke, is the third
77 most common cardiovascular disease.¹ The annual incidence of PE is approximately 1 per
78 1,000 people.² PE occurs when emboli occlude the pulmonary arteries and may cause
79 complications, such as arrhythmias, right ventricular (RV) failure, cardiogenic shock, and
80 even death.³ Effective risk stratification is crucial for treating PE, as it helps identify patients
81 that may benefit from thrombolytic therapies on top of systemic anticoagulation. The 2019
82 European Society of Cardiology (ESC) guideline on PE classifies patients into different risk
83 groups based on the presence of hemodynamic instability, RV dysfunction, elevated cardiac
84 enzymes, and the PE risk index (PESI).⁴ Thrombolytic therapy is recommended for high-risk
85 patients with PE, who are defined as having hemodynamic instability. The benefit of early
86 reperfusion in patients without hemodynamic instability but with other clinical indicators of
87 poor outcomes remains unknown. However, patients with acute PE may develop acute RV
88 failure days after the emboli event, followed by hemodynamic instability and clinical
89 deterioration. Prompt recognition of patients who are prone to clinical deterioration is
90 important, but clinical predictors are currently lacking.

91 Miller et al. first developed an index based on invasive pulmonary angiography to describe
92 the thrombus burden and the severity of PE to evaluate the treatment response of systemic

93 thrombolysis. However, the clinical utility of the Miller index is limited by its invasive nature.

94 ⁵ Qanadli et al. later developed an index (PAOI) based on computed tomography pulmonary

95 angiography (CTPA) which correlated well with the Miller index and could predict RV

96 dilatation. The Qanadli index is of limited clinical utility due to its complexity in score

97 calculation. ⁶ Studies revealed that the Qanadli index is strongly predictive of high-risk

98 patients. ^{7,8} However, other studies revealed no significant correlation between the

99 thrombus burden and clinical risks. ^{9,10}

100 This study primarily aimed to develop a simplified imaging model with good clinical

101 accessibility to predict the clinical deterioration of patients with acute PE.

102 **Materials and methods**

103 **Materials**

104 This retrospective study used the cardiovascular databank of the National Cheng Kung

105 University Hospital. The enrollment period spanned from January 1, 2008, to December 31,

106 2019, and included patients diagnosed with PE under the International Classification of

107 Disease, ninth or tenth revision. This study adhered to the Declaration of Helsinki and

108 obtained approval from the Human Research and Ethics Committee of the National Cheng

109 Kung University Hospital (IRB number: B-ER-109-102). An additional group of patients from

110 Chi Mei Medical Center, which is another tertiary medical center, from January 1, 2008, to

111 December 31, 2021, was included for external validation. The external validation group also

112 received approval from the Human Research and Ethics Committee of the Chi Mei Medical
113 Center (IRB number: CMMC11011-002).

114 This study applied certain exclusion criteria. Patients with septic, tumor, or fat emboli,
115 tumor invasion or pulmonary artery encasement, and stump thrombosis were excluded
116 from the study, as well as patients with only segmental or subsegmental PE, where the
117 thrombi were too small to cause clinical symptoms. Further, cases with poor image quality or
118 no diagnostic CTPA were excluded. Furthermore, patients with CT-defined chronic thrombus
119 were excluded due to differing prognoses. The simplified PESI (sPESI) was calculated.¹¹ The
120 administration of systemic or catheter-directed thrombolysis was recorded for each patient.

121 **Obstruction index determination**

122 Two specialists, who were unaware of the patient's clinical data, evaluated the images.
123 Two indices, namely the Miller obstruction index and the Qanadli index, were calculated
124 based on CTPA. The Miller obstruction index is calculated as $\Sigma (n.d)$, where n represents the
125 number of segmental arteries with thrombus (range: 1–16) and d is the presence (1) or
126 absence (0) of obstruction. According to Miller et al., the right pulmonary artery has nine
127 major segmental arteries (three to the upper lobe, two to the middle lobe, and four to the
128 lower lobe), and the left pulmonary artery has seven major segmental arteries (two to the
129 upper lobe, two to the lingula, and four to the lower lobe).⁵ The Qanadli index is calculated
130 as $\Sigma (n.d)/40 \times 100$, where n is the number of segmental arteries with thrombus (ranging

131 from 1 to 20), and d is the degree of obstruction (range: 0–2). Both pulmonary arteries have
132 ten segmental arteries (three to the upper lobes, three to the middle lobe and lingula, and
133 four to the lower lobes). The degree of obstruction ranges from 0 (no obstruction) to 1
134 (partial obstruction) to 2 (nearly total obstruction).⁶

135 The degree of obstruction of the central segments was also scored, using the same scale
136 of 0 (no obstruction) to 1 (partial obstruction) to 2 (nearly total obstruction), to
137 comprehensively assess the pulmonary circulation and evaluate the entire pulmonary
138 vasculature. The central pulmonary artery was divided into seven segments based on the
139 lung lobes they supply: the main pulmonary artery, the proximal, middle, and distal parts of
140 bilateral pulmonary arteries. The proximal segment of the right and left pulmonary arteries
141 represents the area between the branching from the main pulmonary artery to the
142 branching of the segmental arteries to the upper lobe. The middle segment lies between the
143 upper lobe segmental arteries and the middle lobe segmental arteries, while the distal
144 segment is distal to the segmental arteries to the middle lobe. The transverse section of the
145 pulmonary artery primarily determines the obstruction percentage (Figure 1).

146 **Proposed models**

147 Six models were developed based on the location (central versus peripheral) and the
148 degree (nearly total versus partial) of obstruction. The peripheral arteries are the segmental
149 pulmonary arteries. Model 1 represents the sum of nearly totally obstructed peripheral

150 arteries. Model 2 is the sum of nearly totally obstructed central and peripheral arteries.
151 Model 3 contains the Qanadli index, which is the sum of peripheral pulmonary artery
152 obstruction. Model 4 combines central and peripheral pulmonary artery obstruction. Model
153 5 comprises the sum of nearly totally obstructed central arteries. Model 6 is the sum of
154 central pulmonary artery obstruction. A seventh model, in addition to the six pre-specified
155 models, was developed by performing univariate logistic regression and selecting the
156 statistically significant parts of pulmonary arteries that impact the outcome (Figure 1). The
157 analysis included the combination of models 1 to 7 together with the sPESI. Further
158 discussions were conducted when there is a discrepancy in judgment until a conclusion is
159 reached.

160 **Outcomes**

161 Two specialists carefully reviewed the electric medical records of enrolled patients. The
162 outcome included clinical deterioration, which is death from PE, cardiopulmonary
163 resuscitation, mechanical ventilation, vasopressor therapy for systemic arterial hypotension,
164 thrombolysis, catheter-directed therapy, and surgical embolectomy¹². Each inpatient was
165 followed up until discharged, while outpatients were followed up for 1 month. PE-related
166 death was analyzed as a separate outcome.

167 **Statistical analysis**

168 Continuous data are presented as the mean \pm standard deviation while dichotomous data

169 as numbers and percentages. The Wilcoxon Rank Sum test was used for comparisons of
170 continuous variables. Fisher's exact test was used for categorical variables.

171 Variables associated with clinical deterioration were identified using univariate logistic
172 regression analysis along with Bonferroni correction and false discovery rate. Multivariate
173 logistic regression was used to analyze the combination of different models plus sPESI.
174 Model performance was calculated by the area under the curve (AUC) of the receiver
175 operating characteristic curve. The accuracy, sensitivity, and specificity were calculated. The
176 category-free NRI and IDI were used to quantify the improvement of the proposed models
177 plus sPESI in comparison with the reference model, which is the sPESI in our study. The
178 Bland-Altman analysis of agreement and the interanalysis correlation coefficient were used
179 to assess the intra- and inter-rater reliability. Finally, a nomogram combining the imaging
180 model and sPESI was proposed. Statistical software R (Version 4.0.2 for Windows) was used
181 for all statistical tests. All statistical tests were 2-sided, and a *P*-value of <0.05 was
182 considered statistically significant.

183 **Results**

184 **Study population**

185 A total of 509 patients with PE were retrospectively screened. The exclusions comprised
186 111, 37, 40, and 111 patients with only segmental or subsegmental PE, chronic PE, other PE
187 etiologies, and suboptimal image quality for evaluation, respectively (Figure S1). Finally, the

188 analysis included 210 patients (age: 65 ± 16 years; male: 40%), including 170 (81%) with no
189 clinical deterioration and 40 (19%) with clinical deterioration. The baseline clinical
190 characteristics were balanced between patients with and without clinical deterioration apart
191 from the sPESI. The sPESI was statistically significantly higher in the group with clinical
192 deterioration (2.55 ± 1.47 vs. 1.42 ± 1.13 , $P < 0.01$). Among the 40 patients with clinical
193 deterioration, 21 (53%) received systemic thrombolysis. The Miller index and the Qanadli
194 index were higher in the group with clinical deterioration (Table 1).

195 This study retrospectively screened 319 patients from another tertiary medical center,
196 with 209 patients being excluded (Figure S2). Finally, the external validation included 109
197 patients (age: 64 ± 17 years; male: 43%), including 84 (77%) with no clinical deterioration
198 and 25 (23%) with clinical deterioration (Table S1).

199 **Degree of obstruction and clinical outcomes**

200 The sPESI demonstrated predictive ability for mortality in patients with acute PE, with an
201 AUC of 0.740. However, both the Miller and Qanadli indices had limited predictive ability of
202 mortality, with AUC values of 0.635 and 0.578, respectively. Additionally, the sPESI exhibits
203 the best performance in predicting clinical deterioration, with an AUC of 0.724. The Miller
204 and Qanadli indices can predict clinical deterioration, with AUC values of 0.624 and 0.678,
205 respectively (Figure 2). The external validation group demonstrated similar results (Figure
206 S3). The sPESI demonstrated predictive ability for both mortality and clinical deterioration,

207 while the Miller and Qanadli indices have low predictive ability for mortality.

208 **Comparison of the predictive ability of different models**

209 We compared models 1 to 6 to assess the impact of different locations (central versus

210 peripheral) and levels of obstruction (partial versus nearly total) on clinical deterioration.

211 Models 1 and 2 were compared to examine whether adding nearly total occluded central

212 pulmonary arteries will improve the predictive ability. Models 1 and 2 exhibit nearly

213 identical predictive abilities with an AUC of 0.70, along with the same accuracy of 0.82.

214 Furthermore, models 3 and 4 were compared to explore the additive effect of central

215 pulmonary arteries. Model 4 demonstrated similar predictive ability (AUC: 0.69) and

216 accuracy (0.81) compared to model 3 (AUC: 0.68 and accuracy: 0.81). Models 5 and 6 were

217 designed to analyze the predictive ability of obstruction of central pulmonary arteries alone.

218 Model 6 has a better predictive ability (AUC: 0.68) compared to model 5 (AUC: 0.63), while

219 both models have similar accuracy (0.81). Finally, model 7 is the summation of statistically

220 significant variables calculated on univariate analysis. It is composed of the first, third, sixth,

221 and eighth segmental arteries of the right pulmonary artery, the third to ninth segmental

222 arteries of the left pulmonary artery, the middle right pulmonary artery, the main pulmonary

223 artery, and the left proximal to distal pulmonary arteries (Table S2). Model 7 demonstrated

224 the best predictive ability among all the models (AUC: 0.72) (Table 2).

225 The external validation group analysis revealed similar results. Model 6, which is the

226 summation of partially and totally occluded central pulmonary arteries, exhibited the best
227 predictive ability in the external validation group (Table S3).

228 **Integrated discrimination index (IDI) and net reclassification index (NRI)**

229 The addition of sPESI to models 1 to 7 resulted in an improved predicting value, with an
230 increased mean AUC from 0.68 to 0.77 and increased mean accuracy from 0.82 to 0.86.
231 Model 7 plus sPESI demonstrated the best predictive ability with an AUC of 0.80 (95%
232 confidence interval [CI]: 0.72–0.88), while model 4 plus sPESI achieved the highest accuracy
233 of 0.87 (Table 2, Table S4). The external validation group analysis revealed similar results,
234 with an increased mean AUC from 0.73 to 0.84 and increased mean accuracy from 0.79 to
235 0.83 after adding sPESI to the models (Table S3). Statistically significant improvements in
236 predicting clinical deterioration were observed based on IDI, with the IDI ranging from 0.02
237 to 0.09, when comparing models 1 to 7 added to the sPESI with sPESI alone. The NRI
238 demonstrated an increased predictive ability of models 1–7 with the addition of sPESI (Table
239 3). The IDI and NRI of the external validation group revealed an improvement in the
240 predicting ability of the models in combination with sPESI compared to sPESI alone (Table
241 S5). Overall, the combination of clinical risk factors and the obstruction severity on CTPA
242 provides a better prediction of clinical deterioration.

243 Nomograms based on the models plus sPESI can be used as a tool in the clinical setting to
244 predict prognosis (Figure S4).

245 **Inter- and intra-rater variability**

246 Model 3, which is the Qanadli index, is used to test the intra- and inter-rater variability.

247 The intra- and inter-rater correlation coefficients of model 3 were 0.995 (95% CI: 0.993–

248 0.996) and 0.989 (95% CI: 0.986–0.992), respectively (Table S6). The Bland-Altman analysis

249 revealed no intra-rater and inter-rater bias in the calculation of model 3 scores (Figure S5).

250 **Discussion**

251 Our study revealed that the sPESI can predict clinical deterioration in patients with PE,

252 and the obstruction level on CTPA can predict mortality and clinical deterioration. After the

253 addition of central segments and partially occluded segments, the predictivity ability is

254 nearly identical. Calculating the nearly totally obstructed 20 peripheral segments is an

255 efficient method that balances predictive ability and clinical usability. Combining the severity

256 of obstruction on the image with sPESI improves the predictive ability for clinical

257 deterioration compared to sPESI alone.

258 Animal studies have revealed that acute pulmonary artery obstruction increases

259 pulmonary artery pressure and pulmonary vascular resistance.^{13,14} Severe pulmonary

260 hypertension may cause RV failure, clinical deterioration, and hemodynamic instability.

261 Currently, discrepancies exist in the literature regarding whether PA clot burden could reflect

262 severity. Some studies revealed thrombus burden as a significant predictor of death in

263 patients with acute PE¹⁵⁻¹⁷, but others have not.^{9,10} The ESC recommended against using the

264 anatomical burden and emboli characteristics to determine PE severity.¹⁸ Our study
265 revealed a positive relationship between the clot burden and both mortality and clinical
266 deterioration, indicating the total burden as not the only affecting factor of clinical
267 deterioration. The obstruction site together with the clot burden is influential in predicting
268 clinical deterioration.

269 Calculating only the occluded central pulmonary arteries had the lowest predictability of
270 clinical deterioration, possibly because proximal artery occlusion does not necessarily
271 reduce distal blood flow. Including the clot burden of the central pulmonary arteries to the
272 peripheral pulmonary arteries yielded similar predictive ability compared to calculating
273 obstructed peripheral pulmonary arteries alone. Similarly, including partially occluded
274 pulmonary arteries yielded similar predictive ability as to calculating the nearly total
275 occluded arteries alone. This indicates a forward blood flow passing through partially
276 occluded arteries to the distal circulation.

277 The 2019 ESC guidelines on PE management classify patients into high, intermediate, and
278 low-risk groups, and recommended treatment options based on risk strata. However,
279 approximately 5% of patients initially classified as intermediate risk will develop
280 hemodynamic decompensation.¹⁹ Our study aims to identify methods to predict clinical
281 deterioration in this specific group of patients, where the benefits of early thrombolytic
282 therapy may outweigh the risk of bleeding. Huang et al. used a three-dimensional CT

283 method to estimate the total embolic burden and revealed a positive correlation between
284 the total embolic volume and impending shock.²⁰ Additionally, our models demonstrated a
285 positive correlation between the severity of obstruction and clinical deterioration, offering a
286 straightforward and easily applicable method to determine severity in the clinical setting.

287 The sPESI, which includes age, cancer, chronic cardiopulmonary diseases, heart rate,
288 systolic blood pressure, and oxyhemoglobin levels, can predict the 30-day mortality of
289 patients with PE.¹¹ Our study revealed that the sPESI predicted clinical deterioration.
290 However, adding the extent of obstruction of pulmonary improves the ability to predict
291 clinical deterioration since the variables included in the sPESI are not specific to PE alone.
292 Our models, increased the predictive ability when added to sPESI, as evidenced by positive
293 NRI and IDI values. The low inter- and intra-observer variability indicates good agreement
294 between the two investigators. The nomogram combining model 1 (totally obstructed
295 peripheral arteries) and the sPESI (Figure S4) is a simple and reproducible tool to aid
296 physicians in assessing the prognosis of patients with acute PE.

297 Current treatment guidelines for acute PE recommend systemic thrombolysis for patients
298 who present with hemodynamic instability,^{21,22} but the management of patients without
299 hemodynamic instability but with unstable clinical features or evidence of RV dysfunction on
300 imaging remains uncertain. Previous studies revealed that treating patients with acute PE
301 with systemic thrombolysis on a background of heparin lowers the risk of developing

302 in-hospital death, clinical deterioration, or hemodynamic decompensation.^{19,23} Additionally,
303 a meta-analysis demonstrated that treating acute PE with thrombolytic therapy lowers
304 mortality, but increases the risk of major bleeding.²⁴ The benefit of thrombolytic therapy
305 may outweigh the risk of bleeding in certain normotensive patients with acute PE with
306 high-risk features. Therefore, developing a more precise prediction method to identify the
307 patients prone to clinical deterioration is essential. Our study may help identify the patients
308 suitable for further investigation into whether the benefit of thrombolytic therapy may
309 outweigh the risk of bleeding.

310 This study has several limitations, including its small sample size and its retrospective
311 design, which prevents assessment of the effects on clinical decision-making and patient
312 outcomes. Additionally, the inclusion of only Asian patients limits the generalizability of the
313 models.

314 In conclusion, our study established a positive correlation between the level of pulmonary
315 artery obstruction and both mortality and clinical deterioration. The combination of
316 calculating nearly totally obstructed peripheral segments and sPESI provides improved
317 predictive ability for clinical deterioration. These findings may offer physicians a tool for
318 predicting the prognosis of patients diagnosed with acute PE.

319

320 **Funding**

321 This study was supported by the grants from National Cheng Kung University Hospital,

322 Tainan, Taiwan (NCKUH-11003021) and by the grants from An Nan Hospital, China Medical

323 University, Tainan, Taiwan (ANHRF112-29).

324

325 **Disclosures**

326 All the authors declare no conflict of interest.

327

328

329 **Supplementary material**

330 Figure S1. Flow Diagram of the Study Cohort

331 Figure S2. Flow Diagram of the Validation Cohort

332 Table S1. Baseline Characteristics of Patients with Acute Pulmonary Embolism with and

333 Without Clinical Deterioration in the External Validation Group

334 Figure S3. The Area Under the Receive Operating Characteristic for the sPESI, Miller Index,

335 and Qanadli Index

336 Table S2. Univariate Regression Analysis of sPESI, Different Segments, and Models in

337 Predicting Clinical Deterioration

338 Table S3. The ROC Analysis of Different Models with and without sPESI in Predicting Clinical

339 Deterioration in the External Validation Group

340 Table S4. Multivariate Regression Analysis of Combination of Models Plus sPESI in Predicting

341 Clinical Deterioration

342 Table S5. The NRI and IDI Comparing the Models Plus sPESI with sPESI in the External

343 Validation Group

344 Table S6. The Inter- and Intra-rater Variability

345 Figure S4. Nomogram Combining Model 1 and sPESI

346 Figure S5. The Bland-Altman Plot

347

348

349 **Reference**

- 350 1. Giuntini C, Di Ricco G, Marini C, Melillo E, Palla A. Pulmonary embolism:
351 epidemiology. *Chest*. 1995;107:3s-9s. doi: 10.1378/chest.107.1_supplement.3s
- 352 2. Heit JA. Epidemiology of venous thromboembolism. *Nature Reviews Cardiology*.
353 2015;12:464-474. doi: 10.1038/nrcardio.2015.83
- 354 3. Huisman MV, Barco S, Cannegieter SC, Le Gal G, Konstantinides SV, Reitsma PH,
355 Rodger M, Noordegraaf AV, Klok FA. Pulmonary embolism. *Nature Reviews Disease*
356 *Primers*. 2018;4:18028. doi: 10.1038/nrdp.2018.28
- 357 4. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman
358 MV, Humbert M, Jennings CS, Jiménez D, et al. 2019 ESC Guidelines for the diagnosis
359 and management of acute pulmonary embolism developed in collaboration with the
360 European Respiratory Society (ERS): The Task Force for the diagnosis and
361 management of acute pulmonary embolism of the European Society of Cardiology
362 (ESC). *Eur Respir J*. 2019;54. doi: 10.1183/13993003.01647-2019
- 363 5. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and
364 heparin in treatment of isolated acute massive pulmonary embolism. *Br Med J*.
365 1971;2:681-684. doi: 10.1136/bmj.2.5763.681
- 366 6. Qanadli SD, El Hajjam M, Vieillard-Baron A, Joseph T, Mesurolle B, Oliva VL, Barré O,
367 Bruckert F, Dubourg O, Lacombe P. New CT index to quantify arterial obstruction in

- 368 pulmonary embolism: comparison with angiographic index and echocardiography.
- 369 *AJR Am J Roentgenol.* 2001;176:1415-1420. doi: 10.2214/ajr.176.6.1761415
- 370 7. Guo F, Zhu G, Shen J, Ma Y. Health risk stratification based on computed tomography
- 371 pulmonary artery obstruction index for acute pulmonary embolism. *Sci Rep.*
- 372 2018;8:17897. doi: 10.1038/s41598-018-36115-7
- 373 8. Yu T, Yuan M, Zhang Q, Shi H, Wang D. Evaluation of computed tomography
- 374 obstruction index in guiding therapeutic decisions and monitoring percutaneous
- 375 catheter fragmentation in massive pulmonary embolism. *J Biomed Res.*
- 376 2011;25:431-437. doi: 10.1016/s1674-8301(11)60057-2
- 377 9. Araoz PA, Gotway MB, Trowbridge RL, Bailey RA, Auerbach AD, Reddy GP, Dawn SK,
- 378 Webb WR, Higgins CB. Helical CT pulmonary angiography predictors of in-hospital
- 379 morbidity and mortality in patients with acute pulmonary embolism. *J Thorac*
- 380 *Imaging.* 2003;18:207-216. doi: 10.1097/00005382-200310000-00001
- 381 10. Ghaye B, Ghuysen A, Willems V, Lambermont B, Gerard P, D'Orio V, Gevenois PA,
- 382 Dondelinger RF. Severe pulmonary embolism: pulmonary artery clot load scores and
- 383 cardiovascular parameters as predictors of mortality. *Radiology.* 2006;239:884-891.
- 384 doi: 10.1148/radiol.2392050075
- 385 11. Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, Otero R, Monreal M,
- 386 Muriel A, Yusen RD. Simplification of the pulmonary embolism severity index for

- 387 prognostication in patients with acute symptomatic pulmonary embolism. *Arch*
388 *Intern Med.* 2010;170:1383-1389. doi: 10.1001/archinternmed.2010.199
- 389 12. Vedovati MC, Germini F, Agnelli G, Becattini C. Prognostic role of embolic burden
390 assessed at computed tomography angiography in patients with acute pulmonary
391 embolism: systematic review and meta-analysis. *J Thromb Haemost.*
392 2013;11:2092-2102. doi: 10.1111/jth.12429
- 393 13. Elliott CG. Pulmonary physiology during pulmonary embolism. *Chest.*
394 1992;101:163s-171s. doi: 10.1378/chest.101.4_supplement.163s
- 395 14. Sharma GV, McIntyre KM, Sharma S, Sasahara AA. Clinical and hemodynamic
396 correlates in pulmonary embolism. *Clin Chest Med.* 1984;5:421-437.
- 397 15. van der Meer RW, Pattynama PM, van Strijen MJ, van den Berg-Huijsmans AA,
398 Hartmann IJ, Putter H, de Roos A, Huisman MV. Right ventricular dysfunction and
399 pulmonary obstruction index at helical CT: prediction of clinical outcome during
400 3-month follow-up in patients with acute pulmonary embolism. *Radiology.*
401 2005;235:798-803. doi: 10.1148/radiol.2353040593
- 402 16. Wu AS, Pezzullo JA, Cronan JJ, Hou DD, Mayo-Smith WW. CT pulmonary angiography:
403 quantification of pulmonary embolus as a predictor of patient outcome--initial
404 experience. *Radiology.* 2004;230:831-835. doi: 10.1148/radiol.2303030083
- 405 17. Engelke C, Rummeny EJ, Marten K. Acute pulmonary embolism on MDCT of the chest:

- 406 prediction of cor pulmonale and short-term patient survival from morphologic
407 embolus burden. *AJR Am J Roentgenol.* 2006;186:1265-1271. doi:
408 10.2214/ajr.05.0650
- 409 18. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady
410 AJ, Ferreira D, Janssens U, et al. Guidelines on the diagnosis and management of
411 acute pulmonary embolism: the Task Force for the Diagnosis and Management of
412 Acute Pulmonary Embolism of the European Society of Cardiology (ESC). *Eur Heart J.*
413 2008;29:2276-2315. doi: 10.1093/eurheartj/ehn310
- 414 19. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E,
415 Bouvaist H, Brenner B, Couturaud F, et al. Fibrinolysis for patients with
416 intermediate-risk pulmonary embolism. *N Engl J Med.* 2014;370:1402-1411. doi:
417 10.1056/NEJMoa1302097
- 418 20. Huang WM, Wu WJ, Yang SH, Sung KT, Hung TC, Hung CL, Yun CH. Quantitative
419 volumetric computed tomography embolic analysis, the Qanadli score, biomarkers,
420 and clinical prognosis in patients with acute pulmonary embolism. *Sci Rep.*
421 2022;12:7620. doi: 10.1038/s41598-022-11812-6
- 422 21. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman
423 MV, Humbert M, Jennings CS, Jiménez D, et al. 2019 ESC Guidelines for the diagnosis
424 and management of acute pulmonary embolism developed in collaboration with the

- 425 European Respiratory Society (ERS). *Eur Heart J*. 2020;41:543-603. doi:
426 10.1093/eurheartj/ehz405
- 427 22. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ,
428 Huisman MV, Kearon C, King CS, Knighton AJ, et al. Antithrombotic Therapy for VTE
429 Disease: Second Update of the CHEST Guideline and Expert Panel Report. *Chest*.
430 2021;160:e545-e608. doi: 10.1016/j.chest.2021.07.055
- 431 23. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase
432 compared with heparin alone in patients with submassive pulmonary embolism. *N*
433 *Engl J Med*. 2002;347:1143-1150. doi: 10.1056/NEJMoa021274
- 434 24. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, Kumbhani
435 DJ, Mukherjee D, Jaff MR, Giri J. Thrombolysis for pulmonary embolism and risk of
436 all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis.
437 *Jama*. 2014;311:2414-2421. doi: 10.1001/jama.2014.5990
- 438
- 439

440 **Tables**

441 **Table 1. Baseline Characteristics of Patients with Acute Pulmonary Embolism with and**

442 **without Clinical Deterioration**

	Overall (N = 210)	With clinical deterioration (N = 40)	Without clinical deterioration (N = 170)	p-value
Age (years old)	64.98 ± 16.18	65.47 ± 17.44	64.86 ± 15.92	.66
Sex (male)	85 (40%)	18 (45%)	67 (39%)	.59
Body mass index (kg/m ²)	25.99 ± 5.84	25.26 ± 4.93	26.16 ± 6.03	.98
sPESI	1.63 ± 1.28	2.55 ± 1.47	1.42 ± 1.13	<.01
Cancer	65 (31%)	12 (30%)	53 (31%)	.99
Hypertension	115 (55%)	23 (58%)	92 (54%)	.73
Diabetes mellitus	43 (20%)	6 (15%)	37 (22%)	.39
Coronary artery disease	19 (9%)	3 (8%)	16 (9%)	.99
Heart failure	27 (13%)	6 (15%)	21 (13%)	.61
Atrial fibrillation	26 (12%)	7 (18%)	19 (11%)	.29
Old stroke	19 (9%)	3 (8%)	16 (9%)	.99
Risk				
High	15 (7%)	11 (28%)	4 (2%)	
Intermediate	119 (57%)	23 (58%)	96 (56%)	<.01
Low	76 (35%)	6 (15%)	70 (41%)	
Systemic t-PA	21 (10%)	21 (53%)	0 (0%)	<.01
Miller index	11.30 ± 4.33	12.88 ± 3.28	10.93 ± 4.47	.01
Qanadli index	20.37 ± 9.31	25.27 ± 7.90	19.21 ± 9.26	<.01

443 Data are presented as mean ± SD or N (%)

444 Abbreviations: sPESI, simplified Pulmonary Embolism Severity Index.

445

446 **Table 2. The ROC Analysis of Different Models with and without sPESI in Predicting Clinical**

447 **Deterioration**

Models	Peripheral	Central	Partial occlusion	Nearly total occlusion	sPESI	AUC (95% CI)	Accuracy
Model 1	●			●		0.6996 (0.6148-0.7843)	0.8238
Model 2	●	●		●		0.6996 (0.6160-0.7832)	0.8238
Model 3	●		●	●		0.6777 (0.5886-0.7669)	0.8095
Model 4	●	●	●	●		0.6895 (0.6015-0.7774)	0.8143
Model 5		●		●		0.6254 (0.5342-0.7167)	0.8095
Model 6		●	●	●		0.6802 (0.5915-0.7690)	0.8095
Model 7	Significant segments on univariate analysis					0.7222 (0.6404-0.8040)	0.819
Model 1 + sPESI	●			●	●	0.7753 (0.6914-0.8592)	0.8619
Model 2 + sPESI	●	●		●	●	0.7765 (0.6914-0.8615)	0.8571
Model 3 + sPESI	●		●	●	●	0.7777 (0.6937-0.8617)	0.8619
Model 4 + sPESI	●	●	●	●	●	0.7824 (0.6990-0.8657)	0.8667
Model 5 + sPESI		●		●	●	0.7418 (0.6467-0.8370)	0.8333
Model 6 + sPESI		●	●	●	●	0.7659 (0.6752-0.8566)	0.8476
Model 7 + sPESI	Significant segments on univariate analysis				●	0.8004 (0.7204-0.8805)	0.8619

448 Abbreviations: AUC, area under curve; ROC, receiver operating characteristic; sPESI,

449 simplified Pulmonary Embolism Severity Index

450

451 **Table 3. The NRI and IDI Comparing Models Plus sPESI with sPESI**


Models	NRI (95% CI)	IDI (95% CI)
Model 1 + sPESI	0.1294 (-0.0100-0.2688)	0.0700 (0.0245-0.1156)
Model 2 + sPESI	0.1235 (-0.0163-0.2634)	0.0691 (0.0238-0.1144)
Model 3 + sPESI	0.1294 (0.0096-0.2492)	0.0643 (0.0252-0.1034)
Model 4 + sPESI	0.1353 (-0.0036-0.2742)	0.0721 (0.0303-0.1138)
Model 5 + sPESI	-0.0397 (-0.1259-0.0465)	0.0283 (0.0017-0.0550)
Model 6 + sPESI	0.0926 (-0.0175-0.2027)	0.0559 (0.0216-0.0903)
Model 7 + sPESI	0.1294 (-0.0100-0.2688)	0.0950 (0.0489-0.1412)

452 Abbreviations: IDI, integrated discrimination improvement; NRI, net reclassification

453 improvement; sPESI, simplified Pulmonary Embolism Severity Index

454

455 **Figure 1**



Model	Component	Score	Max. score
1	Peripheral arteries 20	0, 2	40
2	Peripheral arteries 20 + Central segments 7	0, 2	54
3	Peripheral arteries 20	0, 1, 2	40
4	Peripheral arteries 20 + Central segments 7	0, 1, 2	54
5	Central segments 7	0, 2	7
6	Central segments 7	0, 1, 2	7
7	Significant segments on univariate analysis	0, 1, 2	32

456

457 **Figure Legends**

458 **Figure 1. Illustration of Models based on Central and Peripheral Pulmonary Arteries and**

459 **Degree of Obstruction.** The left upward illustration is a schematic representation of the

460 pulmonary arterial vasculature. The area in red represents the 20 peripheral segmental

461 pulmonary arteries and the area shaded in yellow represents the central pulmonary arteries,

462 which is further divided into the proximal, middle, and distal parts based on the lung lobes

463 which they supply. The right upward illustration is the scores based on levels of obstruction.

464 The illustrations and the reference on computed tomography are listed below. A score of 0

465 indicates no thrombus, a score of 1 indicates partial obstruction, and a score of 2 indicates

466 nearly total obstruction. The below table is an explanation of models 1 to 7. Model 1

467 represents the sum of nearly total obstructed peripheral arteries. Model 2 is the sum of

468 nearly total obstructed central and peripheral arteries. Model 3 includes the sum of

469 peripheral pulmonary artery obstruction, which is the Qanadli index. Model 4 combines

470 central and peripheral pulmonary artery obstruction. Model 5 comprises the sum of nearly

471 total obstructed central arteries. Model 6 is the sum of central pulmonary artery

472 obstruction.


473 Abbreviations: LA1-10, 1st to 10th segmental pulmonary arteries of the left pulmonary artery;

474 LPA, left pulmonary artery; RA1-10, 1st to 10th segmental pulmonary arteries of the right

475 pulmonary artery; RPA, right pulmonary artery.

476

477 **Figure 2**



478

479 **Figure 2. The Area Under the Receiver Operating Characteristic for the sPESI, Miller Index,**

480 **and Qanadli Index to Predict Mortality and Clinical Deterioration. Abbreviations: sPESI,**

481 **simplified Pulmonary Embolism Severity Index**

482